TY - JOUR
T1 - Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival
AU - Marsh, J. Wallis
AU - Finkelstein, Sydney D.
AU - Demetris, Anthony J.
AU - Swalsky, Patricia A.
AU - Sasatomi, Eizaburo
AU - Bandos, Andriy
AU - Subotin, Michael
AU - Dvorchik, Igor
N1 - Funding Information:
Supported by a grant from The Pittsburgh Foundation, funded by The R. Green Annan Medical Fund, the William J. Black Fund, the Simeon M. Jones, Jr. and Katharine Reed Jones Fund, the Anna E. McElhaney Fund, and the Benjamin H and Portia T. Hosler Fund, NIH grant DK49615 (AJD), and a grant from the Steinfurth/Lynd family trust.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - The goal of this study was to determine whether a panel of tumor suppressor gene markers of allelic loss could serve as a representative indicator of gene damage and thereby provide further discriminative power over current staging systems for recurrence-free prognostication in patients undergoing liver transplantation in the presence of hepatocellular carcinoma. The paraffin blocks from 103 cases of hepatocellular carcinoma were obtained, and cellular targets were selected for tissue microdissection genotyping. Tumor suppressor gene loss was based on loss of heterozygosity situated within or adjacent to specific genes of interest (APC, CDKN2A, DCC, MET, MYC1, OGG1, p34, p53, PTEN). Microdissected tissue was amplified using polymerase chain reaction (PCR) with flanking oligonucleotides bearing fluorescent labels designed for GeneScan fragment analysis; PCR products were separated by capillary electrophoresis. Normal microdissected tissue samples for each case were evaluated for informative status with respect to individual alleles for 18 microsatellites at 10 genomic loci - 1p, 3p, 5q, 7q, 8q, 9p, 10q, 17p, 17q, 18q. The measure of allelic loss of heterozygosity combined with tumor number, tumor size, vascular invasion, lobar distribution, and patient gender provide a highly discriminatory model for predicting cancer recurrence after liver transplantation. Using our previously developed artificial neural network model in combination with the genotyping results, unambiguous predictions were made for 91 of the 103 patients (88.3%). Of these, 1 was lost to follow-up, and 9 died recurrence-free less than 3 years posttransplantation. For the remaining 81, the combined models predicted tumor recurrence outcomes with complete accuracy. Microdissection genotyping provides powerful supplementary discriminative information for tumor-free survival.
AB - The goal of this study was to determine whether a panel of tumor suppressor gene markers of allelic loss could serve as a representative indicator of gene damage and thereby provide further discriminative power over current staging systems for recurrence-free prognostication in patients undergoing liver transplantation in the presence of hepatocellular carcinoma. The paraffin blocks from 103 cases of hepatocellular carcinoma were obtained, and cellular targets were selected for tissue microdissection genotyping. Tumor suppressor gene loss was based on loss of heterozygosity situated within or adjacent to specific genes of interest (APC, CDKN2A, DCC, MET, MYC1, OGG1, p34, p53, PTEN). Microdissected tissue was amplified using polymerase chain reaction (PCR) with flanking oligonucleotides bearing fluorescent labels designed for GeneScan fragment analysis; PCR products were separated by capillary electrophoresis. Normal microdissected tissue samples for each case were evaluated for informative status with respect to individual alleles for 18 microsatellites at 10 genomic loci - 1p, 3p, 5q, 7q, 8q, 9p, 10q, 17p, 17q, 18q. The measure of allelic loss of heterozygosity combined with tumor number, tumor size, vascular invasion, lobar distribution, and patient gender provide a highly discriminatory model for predicting cancer recurrence after liver transplantation. Using our previously developed artificial neural network model in combination with the genotyping results, unambiguous predictions were made for 91 of the 103 patients (88.3%). Of these, 1 was lost to follow-up, and 9 died recurrence-free less than 3 years posttransplantation. For the remaining 81, the combined models predicted tumor recurrence outcomes with complete accuracy. Microdissection genotyping provides powerful supplementary discriminative information for tumor-free survival.
UR - http://www.scopus.com/inward/record.url?scp=0038487020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038487020&partnerID=8YFLogxK
U2 - 10.1053/jlts.2003.50144
DO - 10.1053/jlts.2003.50144
M3 - Article
C2 - 12827550
AN - SCOPUS:0038487020
SN - 1527-6465
VL - 9
SP - 664
EP - 671
JO - Liver Transplantation
JF - Liver Transplantation
IS - 7
ER -